Comparative Pharmacology
Head-to-head clinical analysis: DYLOJECT versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYLOJECT versus MECLOFENAMATE SODIUM.
DYLOJECT vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category C
Category C
NSAID
NSAID